Arkolith/Insider Trading/RLAY/Form 4

Bergstrom Donald A

President, R&DRelay Therapeutics, Inc. (RLAY) · full profile →Form 4 · filed Jun 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.6M
Net Open-Market Flow
-$1.6M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)93K$4.12$385K512K
Jun 22, 2026Sell(S)93K$16.94$1.6M419K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)93K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-281059) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML